PFAS CLAIM
ARE YOU OR A LOVED ONE HAVE HAVE THESE INJURIES AFTER BEING EXPOSED TO PFAS?
- Testicular Cancer (males only)
- Thyroid Disease (including Hyperthyroidism, Hypothyroidism, Thyroiditis,
- Hashimoto’s Disease, Grave’s Disease, Goiter, Thyroid Nodules)
- Ulcerative Colitis
- Liver Cancer
- Bladder Cancer
- Blood Cancer (Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma /
- Multiple Myeloma)
- Breast Cancer
- Preeclampsia/Low Birthweight
- Pancreatic Cancer
- Prostate Cancer (males only)
- Thyroid Cancer
You may be entitled to SIGNIFICANT COMPENSATION.
We'll handle everything from filing your claim to fighting for the highest possible settlement. Find Out if You Qualify Today!
How our Team can Help You
The process for filing a claim is very complex and any errors in your application can result in your claim being denied. Our legal team are experts in these types of claims and will guarantee that everything is filed correctly and fight to get you the highest possible settlement amount.
PFAS and Cancer
Per- and polyfluoroalkyl substances (PFAS) are a unique class of chemicals. Their many fluorine-carbon bonds render them both hydrophobic and lipophobic, repelling both water and oil and resistant to degradation. These distinctive properties lend themselves to many applications, from waterproof raincoats to nonstick cookware to firefighting foams. Yet these same properties make them potentially hazardous; some PFAS are highly persistent in the environment and are widely detected in humans, raising concerns about potential health effects. In 2014, the International Agency for Research on Cancer (IARC) Monograph programme classified perfluorooctanoic acid (PFOA), the most well-studied PFAS to date, as a possible human carcinogen.
In 2020, Dr. Hofmann and colleagues published the largest study to date on the associations of PFAS with kidney cancer risk in the Journal of the National Cancer Institute, using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The concentrations of PFOA and other PFAS in participants' blood were similar to those found in the U.S. general population. Importantly, this study measured PFAS prospectively in blood samples collected prior to cancer diagnosis. This approach helps to eliminate bias and can better determine which exposures may be harmful. “We found that study participants with the highest concentrations of PFOA were more than twice as likely to develop kidney cancer compared to those with the lowest concentrations,” said Dr. Hofmann.
